Super Saturated Oxygen (SSO2) Therapy in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Action on Coronary Microcirculation Dysfunction (IC-HOT-MICRO)
STEMI, Coronary Microvascular Dysfunction
About this trial
This is an interventional treatment trial for STEMI focused on measuring STEMI, coronary microcirculatory dysfunction, SSO2 therapy
Eligibility Criteria
Inclusion Criteria: Age >18 years and <80 years ST-segment elevation myocardial infarction within 6 hours of symptom onset with ≥1 mm ST-segment elevation in ≥2 contiguous leads in V1-V4 or new left bundle branch block. Successful PCI of a proximal or medial LAD lesion with commercially available coronary stents and achievement of residual stenosis <50% diameter and thrombolysis-in-myocardial-infarction (TIMI) flow grade 2 or 3. Systemic arterial pO2 greater than or equal to 10.7 kPa or 80 mmHg with or without oxygen supplementation. Patient enrolled in a social security plan or beneficiary of such a plan Consent obtained from the patient before inclusion (Emergency consent) Exclusion Criteria: History of anterior coronary artery bypass grafting (CABG) Previous myocardial infarction History of PCI on the LAD New LAD PCI planned within 30 days. Mechanical complications of STEMI (Patients with ventricular pseudoaneurysm, ventricular septal defect (VSD), or severe mitral valve regurgitation (with or without papillary muscle rupture)), cardiogenic shock, or Presence of an intra-aortic counterpulsation balloon. Valvular stenosis or heart failure, pericardial disease, or nonischemic cardiomyopathy. Known prior left ventricular ejection fraction (LVEF) < 40%, Use of thrombolytic therapy Patients with a contraindication to anticoagulant therapy. Creatinine clearance <30 ml/min/1.73 m2, Hemoglobin <10 g/dL Gastrointestinal or urogenital bleeding within the last two months or any major surgery (including CABG) within six weeks prior to surgery. Female of childbearing age Patient on deferral or participating in another clinical investigation, Protected populations: pregnant women, parturients, nursing mothers; persons deprived of liberty by a judicial or administrative decision; protected adults
Sites / Locations
- University Hospital Grenoble
Arms of the Study
Arm 1
Experimental
SSO2 therapy
After successful PCI of a proximal or middle LAD lesion, the patient will be informed and emergency consent will be obtained. SSO2 therapy will then be performed. Overoxygenated blood will be delivered to the origin of the LAD for 60 minutes. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images